BL-M17D1

DRUG3 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.

Conditions

Breast CancerBreast Cancer Stage IIIColorectal CancerEndometrial NeoplasmsEsophageal CancerFallopian Tube CancerGastric CancerGastroesophageal-junction Cancer

Phase 1

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

RecruitingNCT06500052

Sichuan Baili Pharmaceutical Co., Ltd.Colorectal Cancer, Esophageal Cancer, Gastric Cancer +2

Start: 2024-07-24End: 2026-08-31Target: 20Updated: 2025-09-18

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

RecruitingNCT06503783

Sichuan Baili Pharmaceutical Co., Ltd.Breast Cancer, Solid Tumor

Start: 2024-08-24End: 2026-08-01Target: 20Updated: 2026-01-21

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Active, not recruitingNCT06714617

SystImmune Inc.Breast Cancer Stage III, Endometrial Neoplasms, Fallopian Tube Cancer +11

Start: 2025-04-10End: 2027-12-01Target: 120Updated: 2025-11-04